Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 929

1.

Pulmonary tuberculosis diagnostic practices among people living with the human immunodeficiency virus in Lesotho.

O'Connor DE, Frederix K, Saito S, Maama LB, Hirsch-Moverman Y, Pitt B, Hayes-Larson E, Lebelo L, Shale M, Howard AA.

Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1133-1138. doi: 10.5588/ijtld.17.0297.

PMID:
28911357
2.

Cyclic stretch induced IL-33 production through HMGB1/TLR-4 signaling pathway in murine respiratory epithelial cells.

Chang J, Xia Y, Wasserloos K, Deng M, Blose KJ, Vorp DA, Turnquist HR, Billiar TR, Pitt BA, Zhang MZ, Zhang LM.

PLoS One. 2017 Sep 12;12(9):e0184770. doi: 10.1371/journal.pone.0184770. eCollection 2017.

3.

Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes.

Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, Bushinsky DA.

Am J Nephrol. 2017 Sep 2;46(3):213-221. doi: 10.1159/000479802. [Epub ahead of print]

4.

Quantification of cotinine in dried blood spots as a biomarker of exposure to tobacco smoke.

Ladror D, Pitt B, Funk W.

Biomarkers. 2017 Sep 18:1-7. doi: 10.1080/1354750X.2017.1375558. [Epub ahead of print]

PMID:
28862876
5.

Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.

Ferreira JP, Duarte K, Montalescot G, Pitt B, de Sa EL, Hamm CW, Flather M, Verheugt F, Shi H, Turgonyi E, Orri M, Rossignol P, Vincent J, Zannad F.

Clin Res Cardiol. 2017 Aug 29. doi: 10.1007/s00392-017-1157-3. [Epub ahead of print]

PMID:
28852839
6.

"Only a life lived for others is worth living:" Redox Signaling by Oxygenated Phospholipids in Cell Fate Decisions.

Tyurina YY, Shrivastava I, Tyurin VA, Mao G, Dar HH, Watkins S, Epperly M, Bahar I, Shvedova AA, Pitt B, Wenzel SE, Mallampalli RK, Sadovsky Y, Gabrilovich D, Greenberger JS, Bayır H, Kagan VE.

Antioxid Redox Signal. 2017 Aug 23. doi: 10.1089/ars.2017.7124. [Epub ahead of print]

PMID:
28835115
7.
8.

Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial.

Dauriz M, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Cosmi F, Tavazzi L, Maggioni AP; GISSI‐HF Investigators.

J Am Heart Assoc. 2017 Jul 5;6(7). pii: e005156. doi: 10.1161/JAHA.116.005156.

9.

Declining Risk of Sudden Death in Heart Failure.

Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Køber L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR, McMurray JJV.

N Engl J Med. 2017 Jul 6;377(1):41-51. doi: 10.1056/NEJMoa1609758.

PMID:
28679089
10.

Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist).

Hegde SM, Claggett B, Shah AM, Lewis EF, Anand I, Shah SJ, Sweitzer NK, Fang JC, Pitt B, Pfeffer MA, Solomon SD.

Circulation. 2017 Sep 12;136(11):982-992. doi: 10.1161/CIRCULATIONAHA.117.028002. Epub 2017 Jun 21.

PMID:
28637881
11.

True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis.

Vukadinović D, Lavall D, Vukadinović AN, Pitt B, Wagenpfeil S, Böhm M.

Am Heart J. 2017 Jun;188:99-108. doi: 10.1016/j.ahj.2017.03.011. Epub 2017 Mar 23. Review.

PMID:
28577687
12.

Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data.

Giles TD, Cockcroft JR, Pitt B, Jakate A, Wright HM.

J Hypertens. 2017 Sep;35(9):1758-1767. doi: 10.1097/HJH.0000000000001412.

13.

Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years.

Packer M, Pitt B, Rouleau JL, Swedberg K, DeMets DL, Fisher L.

JACC Heart Fail. 2017 Jun;5(6):399-407. doi: 10.1016/j.jchf.2017.03.003. Epub 2017 May 10.

PMID:
28501522
14.

Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure.

Rafique Z, Weir MR, Onuigbo M, Pitt B, Lafayette R, Butler J, Lopes M, Farnum C, Peacock WF.

J Manag Care Spec Pharm. 2017 Apr;23(4-a Suppl):S10-S19. doi: 10.18553/jmcp.2017.23.4-a.s10.

15.

Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative.

Coiro S, Girerd N, Rossignol P, Bauersachs J, Pitt B, Fay R, Ambrosio G, Solomon SD, Dickstein K, Zannad F.

Clin Res Cardiol. 2017 Apr 28. doi: 10.1007/s00392-017-1116-z. [Epub ahead of print]

PMID:
28455597
16.

Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation.

de Denus S, O'Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, Jutras M, Lavoie J, Solomon SD, Pitt B, Pfeffer MA, Rouleau JL.

N Engl J Med. 2017 Apr 27;376(17):1690-1692. doi: 10.1056/NEJMc1612601. No abstract available.

17.

Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.

Rossignol P, Agarwal R, Canaud B, Charney A, Chatellier G, Craig JC, Cushman WC, Gansevoort RT, Fellström B, Garza D, Guzman N, Holtkamp FA, London GM, Massy ZA, Mebazaa A, Mol PGM, Pfeffer MA, Rosenberg Y, Ruilope LM, Seltzer J, Shah AM, Shah S, Singh B, Stefánsson BV, Stockbridge N, Stough WG, Thygesen K, Walsh M, Wanner C, Warnock DG, Wilcox CS, Wittes J, Pitt B, Thompson A, Zannad F.

Eur Heart J. 2017 Apr 18. doi: 10.1093/eurheartj/ehx209. [Epub ahead of print]

PMID:
28431138
18.

Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?

Ferreira JP, Mentz RJ, Pizard A, Pitt B, Zannad F.

Eur J Heart Fail. 2017 Aug;19(8):974-986. doi: 10.1002/ejhf.814. Epub 2017 Apr 12. Review.

PMID:
28401618
19.

Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.

Anand IS, Claggett B, Liu J, Shah AM, Rector TS, Shah SJ, Desai AS, O'Meara E, Fleg JL, Pfeffer MA, Pitt B, Solomon SD.

JACC Heart Fail. 2017 Apr;5(4):241-252. doi: 10.1016/j.jchf.2016.11.015.

PMID:
28359411
20.

Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction.

Biering-Sørensen T, Shah SJ, Anand I, Sweitzer N, Claggett B, Liu L, Pitt B, Pfeffer MA, Solomon SD, Shah AM.

Eur J Heart Fail. 2017 Aug;19(8):1043-1052. doi: 10.1002/ejhf.789. Epub 2017 Mar 21.

PMID:
28322009

Supplemental Content

Loading ...
Support Center